Dewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions have pathways that are regulated by condensates or arise from the dysfunction of condensates, with programs spanning oncology, neuromuscular, cardiopulmonary, and virology indications. Dewpoint scientists work in Boston, Dresden, and Berlin to translate condensate biology into treatments for the toughest diseases. Learn more at dewpointx.com, and follow us on Twitter and LinkedIn. Scientists or investors interested in biomolecular condensates can also visit condensates.com for news and updates in the field.